|
Consolidated Financial Statement Detail (Details)
|
12 Months Ended | 12 Months Ended | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
USD ($)
|
Dec. 31, 2011
USD ($)
|
Dec. 31, 2010
USD ($)
|
Dec. 31, 2012
Equipment and Furniture [Member]
USD ($)
|
Dec. 31, 2011
Equipment and Furniture [Member]
USD ($)
|
Dec. 31, 2012
Buildings, Leasehold and Building Improvements [Member]
USD ($)
|
Dec. 31, 2011
Buildings, Leasehold and Building Improvements [Member]
USD ($)
|
Dec. 31, 2012
Construction-in-Progress [Member]
USD ($)
|
Dec. 31, 2011
Construction-in-Progress [Member]
USD ($)
|
Dec. 31, 2012
Land [Member]
USD ($)
|
Dec. 31, 2011
Land [Member]
USD ($)
|
Dec. 31, 2012
Options Contract [Member]
USD ($)
|
Dec. 31, 2011
Options Contract [Member]
USD ($)
|
Dec. 31, 2012
Options Contract [Member]
EUR (€)
|
Dec. 31, 2012
Option Contract 1 [Member]
EUR (€)
|
Dec. 31, 2012
Option Contract 2 [Member]
EUR (€)
|
Dec. 31, 2012
Demand Deposits [Member]
USD ($)
|
Dec. 31, 2011
Demand Deposits [Member]
USD ($)
|
Dec. 31, 2012
Money Market Funds [Member]
USD ($)
|
Dec. 31, 2011
Money Market Funds [Member]
USD ($)
|
|
| Cash and Cash Equivalents [Line Items] | ||||||||||||||||||||
| Cash equivalents | $ 7,800,000 | $ 21,100,000 | $ 37,500,000 | $ 27,200,000 | ||||||||||||||||
| Short-term Investments [Abstract] | ||||||||||||||||||||
| Short-term investments | 39,987,000 | 0 | ||||||||||||||||||
| Derivative [Line Items] | ||||||||||||||||||||
| Notional amount of derivative liability | 15,000,000 | |||||||||||||||||||
| Number of foreign exchange option contracts | 2 | |||||||||||||||||||
| Derivative, amount of hedged item | 1,500,000 | 15,000,000 | ||||||||||||||||||
| Derivative, premiums | 1,500,000 | |||||||||||||||||||
| Derivative fair value | 500,000 | |||||||||||||||||||
| Derivative, loss | 700,000 | 300,000 | ||||||||||||||||||
| Receivables [Abstract] | ||||||||||||||||||||
| Trade receivables, net | 7,477,000 | 11,820,000 | ||||||||||||||||||
| Other receivables | 772,000 | 512,000 | ||||||||||||||||||
| Total | 8,249,000 | 12,332,000 | ||||||||||||||||||
| Property, Plant and Equipment [Line Items] | ||||||||||||||||||||
| Property and equipment, gross | 49,532,000 | 56,256,000 | 25,734,000 | 33,483,000 | 21,656,000 | 21,490,000 | 1,832,000 | 973,000 | 310,000 | 310,000 | ||||||||||
| Less: Accumulated depreciation and amortization | (41,389,000) | (43,547,000) | ||||||||||||||||||
| Property and equipment, net | 8,143,000 | 12,709,000 | ||||||||||||||||||
| Depreciation and amortization expense | 4,124,000 | 5,357,000 | 5,721,000 | |||||||||||||||||
| Accrued Liabilities [Abstract] | ||||||||||||||||||||
| Accrued clinical trial costs | 4,702,000 | 140,000 | ||||||||||||||||||
| Accrued management incentive compensation | 3,802,000 | 4,096,000 | ||||||||||||||||||
| Accrued payroll and other benefits | 2,461,000 | 3,007,000 | ||||||||||||||||||
| Accrued severance payments | 490,000 | 1,207,000 | ||||||||||||||||||
| Other | 1,535,000 | 1,562,000 | ||||||||||||||||||
| Total | 12,990,000 | 10,012,000 | ||||||||||||||||||
| Deferred Revenue [Abstract] | ||||||||||||||||||||
| Revenue deferred | 5,900,000 | 12,700,000 | ||||||||||||||||||
| Revenue recognized | $ 9,400,000 | $ 17,600,000 | ||||||||||||||||||